ClinicalTrials.gov
public full text
Public Domain
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck#909960
- Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck#880187
- SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer#1047105
- APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma#865781
- Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy#968224
Record · ID 838353
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive